CRISPR Therapeutics CRSP Collaboration Expense
Collaboration Expense at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept crsp:CollaborationExpense.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's collaboration expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's collaboration expense?
- CRISPR Therapeutics (CRSP) reported collaboration expense of $45.95M in Q1 2026.
- How has CRISPR Therapeutics's collaboration expense changed year-over-year?
- CRISPR Therapeutics's collaboration expense decreased by 20.1% year-over-year, from $57.51M to $45.95M.
- What is the long-term trend for CRISPR Therapeutics's collaboration expense?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's collaboration expense has grown at a 20.5% compound annual growth rate (CAGR), from $101.18M to $213.48M.
- What does collaboration expense mean?
- This captures costs incurred under strategic partnerships or joint development agreements with other entities. It reflects the financial commitment required to share resources, expertise, and risks in the development of new technologies or drug candidates. High levels of this expense indicate a reliance on external partners to accelerate R&D timelines and market access.